These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 32172223)

  • 1. Methodological quality of oncology noninferiority clinical trials.
    Wayant C; Ross A; Vassar M
    Crit Rev Oncol Hematol; 2020 May; 149():102938. PubMed ID: 32172223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Empirical Analysis of Noninferiority Studies in Oncology: Are They Good Enough?
    Haslam A; Gill J; Prasad V
    J Natl Compr Canc Netw; 2020 Feb; 18(2):161-167. PubMed ID: 32023529
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systematic qualitative review of randomised trials conducted in nonsmall cell lung cancer with a noninferiority or equivalence design.
    Paesmans M; Grigoriu B; Ocak S; Roelandts M; Lafitte JJ; Holbrechts S; Berghmans T; Meert AP; Moretti L; Danyi S; Pasleau F; Ameye L; Van Meerhaeghe A; Sculier JP
    Eur Respir J; 2015 Feb; 45(2):511-24. PubMed ID: 25537559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the Justification, Funding, Success, and Survival Outcomes of Randomized Noninferiority Trials of Cancer Drugs: A Systematic Review and Pooled Analysis.
    Gyawali B; Tessema FA; Jung EH; Kesselheim AS
    JAMA Netw Open; 2019 Aug; 2(8):e199570. PubMed ID: 31469391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Most noninferiority trials were not designed to preserve active comparator treatment effects.
    Tsui M; Rehal S; Jairath V; Kahan BC
    J Clin Epidemiol; 2019 Jun; 110():82-89. PubMed ID: 30858020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Need for Combined Assessment of Multiple Outcomes in Noninferiority Trials in Oncology.
    Jatoi I; Gail MH
    JAMA Oncol; 2020 Mar; 6(3):420-424. PubMed ID: 31830235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of reporting of noninferiority and equivalence randomized trials.
    Le Henanff A; Giraudeau B; Baron G; Ravaud P
    JAMA; 2006 Mar; 295(10):1147-51. PubMed ID: 16522835
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical issues and recommendations for noninferiority trials in oncology: a systematic review.
    Tanaka S; Kinjo Y; Kataoka Y; Yoshimura K; Teramukai S
    Clin Cancer Res; 2012 Apr; 18(7):1837-47. PubMed ID: 22317762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A systematic review of noninferiority margins in oncology clinical trials.
    Hashim M; Vincken T; Kroi F; Gebregergish S; Spencer M; Wang J; Kampfenkel T; Lam A; He J
    J Comp Eff Res; 2021 Apr; 10(6):443-455. PubMed ID: 33728935
    [No Abstract]   [Full Text] [Related]  

  • 10. Using a single noninferiority margin or preserved fraction for an entire pharmacological class was found to be inappropriate.
    Althunian TA; de Boer A; Groenwold RHH; Klungel OH
    J Clin Epidemiol; 2018 Dec; 104():15-23. PubMed ID: 30009941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals.
    Bikdeli B; Welsh JW; Akram Y; Punnanithinont N; Lee I; Desai NR; Kaul S; Stone GW; Ross JS; Krumholz HM
    Circulation; 2019 Jul; 140(5):379-389. PubMed ID: 31177811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-inferiority Trial Design in Drug Development: A Primer for Cardiovascular Healthcare Professionals.
    Angeli F; Verdecchia P; Reboldi G
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):229-238. PubMed ID: 31650521
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Empirical Consequences of Current Recommendations for the Design and Interpretation of Noninferiority Trials.
    Aberegg SK; Hersh AM; Samore MH
    J Gen Intern Med; 2018 Jan; 33(1):88-96. PubMed ID: 28875400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pros and Cons of Noninferiority Trials.
    Ofori S; Tornberg SV; Kilpeläinen TP; Tikkinen KAO; Guyatt GH; Witte LPW
    Eur Urol Focus; 2023 Sep; 9(5):711-714. PubMed ID: 37880063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protocol adherence rates in superiority and noninferiority randomized clinical trials published in high impact medical journals.
    Bamat NA; Ekhaguere OA; Zhang L; Flannery DD; Handley SC; Herrick HM; Ellenberg SS
    Clin Trials; 2020 Oct; 17(5):552-559. PubMed ID: 32666826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing noninferiority: Evaluating efficacy of a new treatment without complete data.
    Gao P; Odem-Davis K
    Pharm Stat; 2019 Oct; 18(5):546-554. PubMed ID: 30977258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defining the noninferiority margin and analysing noninferiority: An overview.
    Althunian TA; de Boer A; Groenwold RHH; Klungel OH
    Br J Clin Pharmacol; 2017 Aug; 83(8):1636-1642. PubMed ID: 28252213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninferiority studies with multiple reference treatments.
    Li-Ching H; Miin-Jye W; Hung CS; Shing KK
    Stat Methods Med Res; 2017 Jun; 26(3):1295-1307. PubMed ID: 25792542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Noninferiority drug trials fail to report adequate methodological detail: an assessment of noninferiority trials from 2010 to 2015.
    Hong J; Tung A; Kinkade A; Tejani AM
    J Clin Epidemiol; 2019 Apr; 108():144-146. PubMed ID: 30529004
    [No Abstract]   [Full Text] [Related]  

  • 20. Some issues for the evaluation of noninferiority trials.
    Xie X; Wang M; Ng V; Sikich N
    J Comp Eff Res; 2018 Sep; 7(9):835-843. PubMed ID: 30192159
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.